lung cancer

[Bioengineered] The expression of HSP90 and IL-6 was upregulated and that of androgen receptor was downregulated by knocking down lung cancer metastasis-related protein 1 or GRα in CRPC cells.

[Mauna Kea Technologies] Mauna Kea Technologies announced that, as part of its collaboration with the Lung Cancer Initiative (LCI) at Johnson & Johnson, initial enrollment of patients has begun in a prospective, multi-center, open-label, single-arm clinical feasibility study sponsored by LCI.

[Merck KGaA] Merck KGaA, announced that the European Commission has approved once-daily oral TEPMETKO® (tepotinib) as monotherapy for the treatment of adult patients with advanced NSCLC harboring alterations leading to mesenchymal-epithelial transition factor gene exon 14 (METex14) skipping.

[Scientific Reports] Investigators discovered a mechanical correlation between leucine proline-enriched proteoglycan 1 (LEPRE1) and pelitinib drug sensitivity using in silico statistical methods and confirmed the correlation in acute myeloid leukemia and A549 lung cancer cells.

[Oncogene] Researchers investigated the function of the oncogenic BAP1/ASXL3/BRD4 epigenetic axis in small cell lung cancer by developing a next-generation BAP1 inhibitor.

[Signal Transduction and Targeted Therapy] Scientists indicated that targeting IL6/JAK2/STAT3 signaling in activated microglia might be a promising new approach for inhibiting brain metastasis in NSCLC patients.